Listar por autor "Rincón, D."
Mostrando ítems 1-2 de 2
-
Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort
Alonso, S.; Riveiro-Barciela, M.; Fernández, I.; Rincón, D.; Real, Y.; Llerena, S.; Gea, F.; Olveira, A.; Fernández-Carrillo, C.; Polo, B.; Carrión, J.A.; Gómez, A.; Devesa, M.J.; Baliellas, C.; Castro-Iglesias, Ángeles; Ampuero, J.; Granados, R.; Pascasio, J.M.; Rubín, A.; Salmerón, J.; Badia, E.; Planas, J.M.M.; Lens, S.; Turnes, J.; Montero, J.L.; Buti, M.; Esteban, R.; Fernández-Rodríguez, C.M. (Wiley, 2016-11-09)[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or ... -
Efficacy and safety of HCV-treatment with direct-acting antiviral agents interferon-free, in patients with severe renal impairment in clinical practice
Cabezas, Joaquín; Londoño, M.C.; Llerena, S.; Muñoz, R.; Baliellas, C.; Buti, M.; Pascasio, J.M.; Sáez-Royuela, F.; García-Samaniego, J.; Vega, J. de la; Sánchez-Pobre, P.; Álvarez-Navascues, C.; Carrión, J.A.; Gea, F.; Morillas, R.M.; Fernández-Bermejo, M.; Castro-Iglesias, Ángeles; Rivero, M.; Fernández, J.R.; Berenguer, M.; Moreno, J.J.; Rincón, D.; Calleja, J.L.; Crespo, J. (Elsevier, 2016)